Shares

36 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 09, 2024

BUY
$9.99 - $18.71 $88,441 - $165,639
8,853 Added 69.45%
21,600 $400,000
Q3 2023

Apr 29, 2024

BUY
$9.99 - $18.71 $88,441 - $165,639
8,853 Added 69.45%
21,600 $400,000
Q3 2023

Nov 14, 2023

BUY
$9.99 - $18.71 $88,441 - $165,639
8,853 Added 69.45%
21,600 $400,000
Q2 2023

Apr 29, 2024

BUY
$9.17 - $19.29 $116,889 - $245,889
12,747 New
12,747 $140,000
Q1 2023

May 09, 2024

BUY
$12.53 - $21.71 $159,719 - $276,737
12,747 New
12,747 $171 Million
Q3 2022

May 10, 2024

SELL
$12.21 - $19.7 $45,531 - $73,461
-3,729 Reduced 22.63%
12,747 $177,000
Q3 2022

Mar 22, 2023

SELL
$12.21 - $19.7 $45,531 - $73,461
-3,729 Reduced 22.63%
12,747 $177,000
Q3 2022

Nov 14, 2022

SELL
$12.21 - $19.7 $45,531 - $73,461
-3,729 Reduced 22.63%
12,747 $178,000
Q2 2022

Jun 20, 2023

BUY
$11.23 - $19.59 $41,876 - $73,051
3,729 Added 29.25%
16,476 $227,000
Q1 2022

May 10, 2024

BUY
$13.37 - $17.79 $220,284 - $293,108
16,476 New
16,476 $268,000
Q1 2022

Jun 20, 2023

BUY
$13.37 - $17.79 $49,856 - $66,338
3,729 Added 29.25%
16,476 $268,000
Q1 2022

Mar 22, 2023

BUY
$13.37 - $17.79 $70,339 - $93,593
5,261 Added 46.91%
16,476 $268,000
Q1 2022

May 12, 2022

BUY
$13.37 - $17.79 $70,339 - $93,593
5,261 Added 46.91%
16,476 $268,000
Q4 2021

Jun 21, 2023

SELL
$14.28 - $19.53 $21,876 - $29,919
-1,532 Reduced 12.02%
11,215 $182,000
Q3 2021

Jun 21, 2023

SELL
$12.99 - $20.47 $19,900 - $31,360
-1,532 Reduced 12.02%
11,215 $166,000
Q2 2021

Jun 21, 2023

SELL
$15.46 - $24.5 $23,684 - $37,534
-1,532 Reduced 12.02%
11,215 $223,000
Q1 2021

May 17, 2024

BUY
$19.33 - $37.75 $216,785 - $423,366
11,215 New
11,215 $258,000
Q1 2021

Jun 26, 2023

SELL
$19.33 - $37.75 $29,613 - $57,833
-1,532 Reduced 12.02%
11,215 $259 Million
Q4 2020

Jun 22, 2023

SELL
$24.48 - $42.47 $37,503 - $65,064
-1,532 Reduced 12.02%
11,215 $277,000
Q3 2020

Jun 26, 2023

SELL
$39.09 - $53.44 $59,885 - $81,870
-1,532 Reduced 12.02%
11,215 $464,000
Q2 2020

May 24, 2024

BUY
$46.7 - $92.04 $523,740 - $1.03 Million
11,215 New
11,215 $537 Million
Q2 2020

Jun 26, 2023

SELL
$46.7 - $92.04 $71,544 - $141,005
-1,532 Reduced 12.02%
11,215 $537,000
Q1 2020

Jul 12, 2023

SELL
$48.35 - $118.68 $74,072 - $181,817
-1,532 Reduced 12.02%
11,215 $706,000
Q4 2019

Jul 12, 2023

SELL
$57.36 - $124.1 $87,875 - $190,121
-1,532 Reduced 12.02%
11,215 $1.39 Million
Q3 2019

Jul 12, 2023

SELL
$58.69 - $80.46 $89,913 - $123,264
-1,532 Reduced 12.02%
11,215 $744,000
Q3 2019

Mar 22, 2023

BUY
$58.69 - $80.46 $90,206 - $123,667
1,537 Added 15.88%
11,215 $744,000
Q3 2019

Nov 14, 2019

BUY
$58.69 - $80.46 $90,206 - $123,667
1,537 Added 15.88%
11,215 $744,000
Q2 2019

Jul 12, 2023

SELL
$77.77 - $120.68 $119,143 - $184,881
-1,532 Reduced 12.02%
11,215 $892,000
Q1 2019

Jul 13, 2023

SELL
$91.83 - $120.68 $281,826 - $370,366
-3,069 Reduced 24.08%
9,678 $1.08 Million
Q4 2018

Jul 13, 2023

SELL
$85.79 - $126.46 $263,289 - $388,105
-3,069 Reduced 24.08%
9,678 $975,000
Q4 2018

Mar 22, 2023

SELL
$85.79 - $126.46 $441,561 - $650,889
-5,147 Reduced 34.72%
9,678 $975,000
Q4 2018

Feb 14, 2019

SELL
$85.79 - $126.46 $441,561 - $650,889
-5,147 Reduced 34.72%
9,678 $975,000
Q3 2018

Jul 13, 2023

SELL
$88.49 - $127.55 $311,661 - $449,231
-3,522 Reduced 27.63%
9,225 $1.17 Million
Q3 2018

Mar 22, 2023

BUY
$88.49 - $127.55 $183,882 - $265,048
2,078 Added 16.3%
14,825 $1.87 Million
Q3 2018

Nov 14, 2018

BUY
$88.49 - $127.55 $413,425 - $595,913
4,672 Added 46.02%
14,825 $1.87 Million
Q2 2018

Aug 15, 2018

BUY
$60.0 - $85.67 $609,180 - $869,807
10,153 New
10,153 $852,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.